The Czech-based pharmaceutical company CB21 Pharma, a spin-off sister company to the developing CBDepot, has made significant strides in the field of medical cannabis. CB21 Pharma has been successful in extending its EU GMP accreditation, opening the door for a larger portfolio of Active Pharmaceutical Ingredients (APIs) generated from cannabis.
CB21: renewed EU GMP certification
In overall, CB21 Pharma has become a significant participant in the pharmaceutical industry. The company focuses on the development and market introduction of innovative treatments. They base on non-psychotropic cannabinoids along with other active ingredients. The organisation has been at the forefront of using the therapeutic potential of cannabinoids, notably cannabidiol (CBD), with a focus on quality and innovation.
CB21 Pharma boasts its own production of various active pharmaceutical ingredients, including isolated natural cannabidiol, synthetic cannabidiol, and hemp extracts. Established in November 2018, the company has rapidly progressed in the pharmaceutical landscape. Finally, by 2020, CB21 Pharma had obtained the necessary permissions and certifications for the production of medicinal substances.
Thus, the recent extension of the EU GMP certification demonstrates CB21 Pharma’s commitment to upholding the highest standards in pharmaceutical production. An honourable certification, EU GMP certification guarantees that products are constantly manufactured and monitored to the highest quality standards. It attests to compliance with strict quality and safety laws.
Expanding the cannabis-derived API portfolio
What is more, with this ongoing certification, CB21 Pharma prepares to increase the number of Active Pharmaceutical Ingredients (APIs) produced from cannabis in its product line. This includes the creation of full spectrum, standardised, and distilled extracts from medical cannabis. They are going to be sold under the names “Cannabis Extractum Raffinatum” and “Cannabis Extractum Normatum.”
These extracts have a lot of potential for the medical cannabis industry. The variety of cannabinoids, terpenes, and other therapeutic substances from the cannabis plant may be present in full spectrum extracts. This variety of substances seems to contribute to the “entourage effect”. Thus, the therapeutic effects of each substance are enhanced when they interact.
Unlocking the therapeutic potential of cannabinoids
Pharmaceuticals made from cannabis have attracted attention for their potential to treat a range of illnesses. These include chronic pain, epilepsy or anxiety. What is more, recent research focus on migraine, acne, ageing, Alzheimer’s disease and many more. In order to further research and guarantee patient access to efficient medicines, high-quality, EU GMP-certified extracts like those made by CB21 Pharma should be readily available.
The accomplishment of CB21 Pharma in extending its EU GMP certification strengthens its position as a pioneer in the Czech pharmaceutical sector. This accomplishment underlines the company’s dedication to R&D. It shows also the growing importance of the Czech Republic in the worldwide market for cannabis-derived pharmaceuticals.
The ongoing EU GMP accreditation shows the company’s commitment to quality and safety. It also predicts a bright future for individuals using cannabis-derived medications to treat a variety of medical problems.